Pharma Patent Expansion Buried in 'Affordable Prescriptions' Bill

What it does

This bill amends patent law to allow pharmaceutical companies holding patents on reference biological products (like biologics) to sue generic/biosimilar competitors and assert up to 20 patents per lawsuit—but with restrictions: no more than 10 patents issued after a specified date, and patents must meet certain criteria (claiming the product itself, listed on the FDA patent list, or filed more than 4 years after approval). Courts can increase this limit if the generic applicant withholds required information or if other good cause exists. The effect is to strengthen patent holders' litigation power against biosimilar entrants while creating procedural hurdles for generics to clear.

Why we flagged it

The bill's core function is to expand patent litigation rights for brand-name biologic manufacturers against biosimilar competitors. Despite the title's consumer-friendly framing ('Affordable Prescriptions'), the operative mechanism restricts generic competition and extends monopoly periods—the opposite of affordability.

What the text implies

• The 20-patent assertion limit per lawsuit, combined with the ability to increase it for 'good cause,' creates a litigation burden that may deter smaller generic manufacturers from challenging patents, even weak ones, due to legal costs.
• The provision allowing courts to increase patent limits if the generic applicant 'fails to provide information' shifts burden of proof and may chill legitimate generic development by creating ambiguity about what information is 'required.'

The full analysis lists 4 implications of this text.

Who stands to gain

brand-name biologic pharmaceutical manufacturers; patent holders in the biologics sector; pharmaceutical litigation firms